![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
Details:
Through the divestment, Enanta will sale a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir) to OMERS Life Sciences. The net sale proceeds will be used to fund the continuing clinical development of virology pipeline.
Lead Product(s): Glecaprevir,Pibrentasvir
Therapeutic Area: Infections and Infectious Diseases Product Name: Mavyret
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: OMERS Life Sciences
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Divestment April 25, 2023